Morgan Stanley Immuno Gen, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$12.46 - $29.95 $51.2 Million - $123 Million	4,109,177 New	4,109,177 $122 Million
Q4 2023 Feb 13, 2024	SELL	$12.46 - $29.95 $8.97 Million - $21.6 Million	-719,914 Reduced 14.91%	4,109,177 $122 Million
Q3 2023 Nov 15, 2023	BUY	$14.09 - $19.87 $21 Million - $29.6 Million	1,490,486 Added 44.64%	4,829,091 $76.6 Million
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $14.9 Million - $79.8 Million	-3,981,093 Reduced 54.39%	3,338,605 $63 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $11.2 Million - $15.1 Million	3,064,478 Added 72.02%	7,319,698 $28.1 Million
Q4 2022 Feb 14, 2023	SELL	$4.55 - $6.31 $2.22 Million - $3.08 Million	-488,254 Reduced 10.29%	4,255,220 $21.1 Million
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $3.33 Million - $4.8 Million	-742,293 Reduced 13.53%	4,743,474 $22.7 Million
Q2 2022 Oct 27, 2022	BUY	$3.15 - $5.76 $759,613 - $1.39 Million	241,147 Added 4.6%	5,485,767 $24.7 Million
Q2 2022 Aug 15, 2022	BUY	$3.15 - $5.76 $759,613 - $1.39 Million	241,147 Added 4.6%	5,485,767 $24.7 Million
Q1 2022 Oct 27, 2022	SELL	$4.26 - $7.48 $1.03 Million - $1.8 Million	-241,147 Reduced 4.4%	5,244,620 $25 Million
Q1 2022 May 13, 2022	BUY	$4.26 - $7.48 $4.42 Million - $7.76 Million	1,037,265 Added 24.65%	5,244,620 $25 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $2.1 Million - $3.32 Million	443,017 Added 11.77%	4,207,355 $31.2 Million
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $18.9 Million - $24.8 Million	3,764,338 New	3,764,338 $21.3 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.